Acupuncture and Related Therapies for Endometriosis: A Network Meta-Analysis of Randomized Controlled Trials

Endometriosis (EMs) is characterized by the endometrial tissue appears, grows, infiltrates, and bleeds repeatedly in the lining of the uterus and in areas outside of the uterus, subsequently causing pain, joint pain, infertility, and nodules. 1 , 2 Clinical manifestations include dysmenorrhea, pelvic pain, dyspareunia, and infertility. 3 It affects approximately 6% to 10% of women of childbearing age. 4 Epidemiological studies reveal that women with EMs have a higher risk of developing ovarian and breast cancer, melanoma, asthma, rheumatoid arthritis, and cardiovascular disease. 5 EMs seriously affects women’s physical health, mental health and quality of life. 6 Therefore, effective interventions remain critical. Currently, the mainstay of drug therapy for EMs is hormone suppressive drugs. 7 In the context of endometriosis-related pain in patients with no current plans to become pregnant: combined oral contraceptives or progestins are low-cost drugs that should be considered as a first-line medical therapy. 8 Although medication is helpful, a large proportion of women (10.0–43.5%) discontinue drugs due to the presence of side effects, such as uterine bleeding, vomiting, breast discomfort, depression, weight gain, and moodiness. 9–12 As such, non-pharmacological approaches are favoured. Acupuncture and it related therapies are characterized by safety and few side effects, and have unique advantages in treating diseases. Acupuncture and related therapies can be roughly divided into invasive and non-invasive methods. Invasive methods include manual acupuncture, electroacupuncture, or ear acupuncture. Non-invasive methods include acupressure, moxibustion, and application of various stimulating patches and pellets. 13 Studies have shown that acupuncture and related therapies are effective and safe ways to relieve dysmenorrhea, shortening the pain duration, and improve the health and quality of life in women with endometriosis-related pain. 14 , 15 Although acupuncture has been investigated for pain relief and there is still a lack of efficacy comparison between different acupuncture and related therapies. It is still unknown which acupuncture-related therapies is more effective in treating endometriosis. The current studies 14–18 are limit to traditional meta-analysis and have not compared different acupuncture-related therapies. Therefore, this work aims to determine the efficacy of each acupuncture therapy on endometriosis by using network meta-analysis (NMA) and ranking the different types of acupuncture-related therapies. We hope that this study will provide clinicians with a clear understanding of the efficacy of different acupuncture treatments, assist patients with endometriosis in selecting the optimal treatment plan, and offer researchers insights into potential avenues for future study designs.

PROSPERO has registered the protocol (CRD42024534622). This research was based on the checklist of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 2020 and extension statement for network meta-analyses (PRISMA-NMA), as well as the reporting items of systematic reviews and meta-analyses related to acupuncture 19 , 20 ( Appendix 1 ). In order to obtain RCTs of acupuncture-related therapies for EMs, we searched four English databases (PubMed, EMBASE, Cochrane Library, and Web of science) and four Chinese databases [China Biology Medicine (CBM), China National Knowledge Infrastructure (CNKI), Wan fang Data, and Chinese Scientific Journal Database (VIP)] for literature on acupuncture-related therapies for endometriosis from inception to 21 April 2024. Use a combination of Medical Subject Headings (MeSH) and free words for retrieval. The MESH keywords included “Acupuncture”, “Acupuncture Points”, “Ear Acupuncture”, “Acupuncture Analgesia”, “Acupuncture Therapy”, “Endometriosis”, “Endometrioma”, “Randomized Controlled Trial”, “RCT”. In addition, manual searches of reference lists in relevant articles. Language is English or Chinese. The complete search strategy is recorded in Appendix 2 . (1) Population: The definitive diagnostic criteria of EMs have been reported in the literature, such as guideline, expert consensus, or textbook. (2) Intervention: The following interventions of treatment group were available: acupuncture (AC), electro-acupuncture (EA), moxibustion (MOX), and other acupuncture-related therapies (such as auricular therapy (AT), acupoint catgut embedding (ACE), acupoint application (AA) or the comparison of various acupuncture-related therapies). (3) Comparison: The control group was acupuncture-related techniques with other techniques or non-acupuncture treatment. (4) Outcomes: The primary outcome measure was the pain visual analogue scale (VAS), while secondary outcomes included serum cancer antigen 125 (CA125) level and response rate. (5) Study Design: Randomized controlled trials (RCTs) from peer-reviewed articles in Chinese or English were included. (1) The same group included three and more interventions. (2) Studies that did not report clear original data of outcome indicators. (3) Similar studies or studies reporting the same results. (4) Conference abstracts and dissertations. Primary outcome: pain visual analogue scale (VAS). Secondary outcomes: serum cancer antigen 125 (CA125) level and response rate. Two reviewers (YW, YG) extracted and collated the following data using a standardized data extraction form include study characteristics (the name of the author and the journal, year of publication), population (age, sample size, disease duration), intervention (name, treatment duration and frequency), outcomes, and adverse effects. They assessed these full-text papers, independently and in duplicate. Another author (GZ) compared the two data extraction forms to evaluated and validated all data extraction. We aimed to calculate mean and standard deviation change from baseline and postintervention values about pain VAS and serum CA125 level. For literature reporting VAS scores for multiple pains, including pelvic pain, dysmenorrhea, and dyspareunia, means and standard deviations were obtained after combining the subgroups. For articles that only reported 95% CI or IQR, they were converted to mean and standard deviation before proceeding to the next step of analysis. 21 , 22 In addition, for the response rate, we classified the clinically cured, effective, apparently effective reported in the literature as response, and the ineffective as non-response. If the trial had been a three-arm trial, it was split and reorganized into all paired two-arm trials. Statistical tables of raw data in Appendix 3 . Review Manager 5.4 and IBM SPSS Statistics 21.0 were used to assess the risk of bias in included literature and calculate the weighted Cohen’s kappa coefficient (κ). 23 Each randomized controlled trial was evaluated according to the following seven items: (1) Random sequence generation (selection bias); (2) Allocation concealment (selection bias); (3) Blinding of participants and personnel (performance bias); (4) Blinding of outcome assessment (detection bias); (5) Incomplete outcome data (attrition bias); (6) Selective reporting (reporting bias); (7) Other bias. Two reviewers (ZX and XL) independently conducted a bias risk assessment. Any disagreements were resolved through consensus. Paired meta-analysis was conducted using the Stata software program (Version 15.0). 24 We analyze each treatment separately to determine the standard mean difference (SMD) in pain VAS scores and serum CA125 level between the different acupuncture-related therapies. For the categorically variable of response rate, risk ratio (RR) was used. The use of fixed or random effects approaches were depended on the presence of heterogeneity, with random effects analysis should be applied when the I-square (I 2 ) was greater than 50%, otherwise a fixed-effect model should be used. To facilitate the comparison of acupuncture-related therapies that were not directly compared in RCTs, we performed NMAs. A network diagram was created to visualize the direct and indirect comparison of different acupuncture-related therapy modes. We used the mvmeta and network packages in Stata and GeMTC 0.14.3 for Bayesian statistical calculations. GeMTC is based on the Markov Chain Monte Carlo (MCMC) consensus model within the Bayesian framework. Simulations are performed using four chains, with the number of iterations set to 400,000 (the first 20,000 for annealing), and the steady state of the model is tested by evaluating the Potential Scale Reduction Factor (PSRF). The ranking probability analysis was conducted to generate the cumulative area under the ranking curve (SUCRA) value for acupuncture-related therapies. Using closed-loop evaluation to compare the inconsistency between the size of direct and indirect effects, if the 95% CI of the inconsistency factor (if) includes 0, then the direct and indirect evidence is consistent. Detailed steps of inconsistency testing in Appendix 4 . Construct a funnel plot to evaluate the presence of small sample effects in the included studies.

A total of 808 relevant experiments were found through literature search. Following the deduplication process, 523 studies have been retained. After reading the title and abstract, there are 169 remaining. Further detailed full-text screening was conducted, with 127 studies excluded because they did not meet the established criteria. Therefore, the final screening included 42 RCTs 25–66 with 3,656 patients with EMs, of which 2 RCTs were in English, 25 , 26 one was a three-arm trial 39 and the others were all two-arm trials. Eleven interventions were included: acupuncture (AC), electro-acupuncture (EA), moxibustion (MOX), auricular therapy (AT), acupoint catgut embedding (ACE), acupoint application (AA), Chinese herb medicine (CH), hormone drugs (western medicine, WM), usual care (UC), sham acupuncture (sAC) and combination therapy (any acupuncture-related therapy combination of the other therapies). Figure 1 illustrates the results of the literature screening. Tables 1 and 2 record the baseline data, detailed acupuncture intervention methods, and outcome indicators of the included studies. Table 1 Baseline Characteristics of the Included Studies References Country Diagnostic Criteria Intervention Control Type of Outcomes Treatment n Years (Mean ± sd)/Range Treatment n Years (Mean ± sd)/Range Li P S 2023 25 China CMA AC 51 30.3±4.6 sAC 53 30.1±4.5 ① Armour M 2021 26 Australia PD Combination therapy 14 33.4±7.3 UC 15 33.4±7.3 ① Xiang DF 2001 27 China GCTNPCM AT 37 22–45 CH 30 24–47 ③ Jin YB 2009 28 China COG AT 40 33.83±5.88 EA 40 34.93±6.15 ③ Zhang H 2018 29 China CMA Combination therapy 42 37±9 CH 41 36±8 ② Xiang DF 2011 30 China CMA AC 30 34.6±5.9 CH 28 34.6±4.9 ①② Chen LN 2010 31 China GCTNPCM AC 35 17–41 WM 26 17–41 ③ Zhang P 2017 32 China OG and GTCM MOX 45 35.8±7.8 WM 45 33.5±6.8 ②③ Jiang BF 2018 33 China GCTNPCM Combination therapy 48 30.25±7.58 WM 48 32.60±10.01 ①③ Teng H 2016 34 China CAIM AC 43 39±4 WM 37 38±3 ② Ma WJ 2023 35 China OG Combination therapy 64 32.42±4.16 WM 64 31.18±4.63 ①②③ Yu WT 2022 36 China CMA Combination therapy 36 32.03±6.64 CH 36 33.89±4.55 ①②③ Lu S 2014 37 China PD MOX 37 30.0±10.23 CH 32 30.0±9.23 ③ Zhang XH 2017 38 China OG Combination therapy 45 22.80±7.20 CH 45 21.70±6.30 ①②③ Niu XX 2012 39 China CMA MOX 31 21–45 Combination therapy 33 21–45 ② CH 29 21–45 An XY 2016 40 China CMA AA 34 28.2 ± 2.2 WM 33 27.8 ± 2.3 ①②③ Chen YB 2021 41 China GTCM Combination therapy 35 35±7 WM 35 34±8 ③ Xu LP 2017 42 China CMA and GCTNPCM Combination therapy 30 31.23 ±3.23 WM 30 31.24±3.22 ①②③ Pan HL 2023 43 China CMA Combination therapy 46 30.51±4.57 WM 45 30.63±4.59 ①②③ Wei W 2015 44 China CMA Combination therapy 30 35.6 ± 8.9 WM 30 36.1 ± 8.3 ②③ Ru HM 2015 45 China OG Combination therapy 135 24–35 WM 134 23–33 ③ Liu YL 2023 46 China CMA Combination therapy 30 33.57±2.36 WM 30 33.12±2.81 ② Yu L 2021 47 China COG Combination therapy 30 34.28±5.17 WM 30 35.57±4.82 ①② Wu JX 2013 48 China GCTNPCM Combination therapy 30 23–46 WM 30 26–45 ③ Zhao JQ 2023 49 China CMA Combination therapy 40 36.98 ± 5.32 CH 40 36.58 ± 3.84 ①③ Wan YT 2022 50 China OG Combination therapy 115 34.97 ± 6.84 CH 60 35.75 ± 8.52 ③ Fang LX 2018 51 China OG, GCTNPCM, and GTCM Combination therapy 40 30.5±2.8 ACE 40 32.5±1.2 ③ Dong Q 2022 52 China GTCM Combination therapy 60 31.72±4.67 MOX 60 31.68±4.56 ③ Zeng R 2010 53 China CAIM Combination therapy 40 35 ±6.5 AC 40 36±6.8 ③ Wang YJ 2018 54 China GCTNPCM Combination therapy 40 37.8±3.5 CH 40 35.2±3.6 ③ Zuo DD 2020 55 China CMA and GCTNPCM Combination therapy 43 39.79 ± 4.55 WM 43 40.98 ± 5.00 ①③ Cong HF 2018 56 China CMA ACE 33 33.94 ± 5.98 AC 32 31.31 ± 5.86 ①③ Men JN 2023 57 China CMA Combination therapy 52 32.63±4.69 CH 47 32.05±4.21 ①②③ Zhang MY 2017 58 China GCTNPCM Combination therapy 60 40.25±2.43 WM 60 40.19±2.3 ② Xi LL 2021 59 China GTCM Combination therapy 40 32±7 WM 40 32±7 ③ Zhang CM 2023 60 China GCTNPCM Combination therapy 40 34.25±7.56 AC 40 34.40±7.47 ③ Chen M 2010 61 China GCTNPCM Combination therapy 34 30.7±5.48 CH 36 30.2±8.21 ③ Feng Y 2014 62 China GCTNPCM Combination therapy 39 30.6±3.1 WM 39 31.3±3.2 ③ Li X 2020 63 China CMA Combination therapy 30 40.2 ± 5.6 WM 30 40.1 ± 5.7 ②③ Hu YG 2019 64 China PD Combination therapy 30 23–46 WM 30 23–47 ③ Liu ZX 2016 65 China GCTNPCM Combination therapy 30 31.64 ± 8.12 WM 30 30.43 ± 7.63 ①③ Du X 2010 66 China PD Combination therapy 93 32–46 WM 93 33–45 ③ Abbreviations : CMA, Chinese Medical Association; PD, Pathologic Diagnosis; GCTNPCM, Guideline for Clinical Trials of New Patent Chinese Medicines; COG, Chinese Obstetrics & Gynecology; OG, Obstetrics and Gynecology; GTCM, Gynecologic Terms in Chinese Medicine; CAIM, Chinese Association of Integrative Medicine; AC, acupuncture; EA, electro-acupuncture; MOX, moxibustion; AT, auricular therapy; ACE, acupoint catgut embedding; AA, acupoint application; CH, Chinese herb medicine; WM, western medicine; UC, usual care; sAC, sham acupuncture. ① VAS scores; ② CA125; ③ response rate. Table 2 Descriptions of the Included Acupuncture and Related Therapies That are Included References Intervention Acupuncture Points Used Retention Time Acupuncturist Qualifications Acupuncture Reaction Timing of Treatment Frequency and Course of Acupuncture Li P S 2023 25 AC Guanyuan (CV4), Sanyinjiao (SP6), Taichong (LR3), Zhaohai (KI6), Qichong (ST30) 30 min Y Y N Three a week for 12 weeks sAC Guanyuan (CV4), Sanyinjiao (SP6), Taichong (LR3), Zhaohai (KI6), Qichong (ST30) 30 min Y N N Three a week for 12 weeks” Armour M 2021 26 Combination therapy AC+UC: Sanyinjiao (SP6), Diji (SP8), Xuehai (SP10), Guilai (ST25), Zusanli (ST36), Zhongji (CV3), Guanyuan (CV4), Taichong (LR3) 25–30 min N Y N Two a week for 8 weeks Xiang DF 2001 27 AT Tingzhong(CO 6.10i ), Pizhixia(AT 4 ), Neifenmi(CO 18 ), Jiaogan(AH 6a ), Neishengzhiqi(TF 2 ) N N N Treatment is started 5 days before menstruation until menstruation occurs Every other day, 4 times a month for 3 months Jin YB 2009 28 AT Neishengzhiqi(TF 2 ), Pizhixia(AT 4 ), Shenmen(TF 4 ), Neifenmi(CO 18 ) 30 min N N Stop treatment during menstruation Every other day for 3 months EA Qihai (CV6), Guanyuan (CV4), Sanyinjiao (SP6), Diji (SP8), Tianshu (ST25), Zigong (EX-CA1) 30 min N Y Stop treatment during menstruation Every other day for 3 months Zhang H 2018 29 Combination therapy AC+CH: Zhongwan (CV12), Xiawan (CV10), Qihai (CV6), Guanyuan (CV4), Shuidao (ST28), Zigong (EX-CA1), Shangliao (BL31), Ciliao (BL32), Zhongliao (BL33), Xialiao (BL34) 30 min N N N Five a week for 3 months Xiang DF 2011 30 AC Zhongwan (CV12), Xiawan (CV10), Qihai (CV6), Guanyuan (CV4), Zhongji (CV3), Wailing (ST26), Shuidao (ST28), Qixue (KI13) 20 min N N Treatment is started 1 week before menstruation until menstruation occurs Three a week for 3 months Chen LN 2010 31 AC Zhongwan (CV12), Xiawan (CV10), Qihai (CV6), Guanyuan (CV4), Zhongji (CV3), Wailing (ST26) 30 min N N Treatment is started 1 week before menstruation until menstruation occurs Once a day for 3 months Zhang P 2017 32 MOX Dazhui (GV14), Mingmen (GV4) N N N N Every other day for 3 months Jiang BF 2018 33 Combination therapy MOX+CH: Zigong (EX-CA1), Zhongji (CV3), Guanyuan (CV4), Qihai (CV6), Zusanli (ST36), Sanyinjiao (SP6) 15–20 min N N N Once a day for 12 weeks Teng H 2016 34 AC Zhongji (CV3), Guanyuan (CV4), Zigong (EX-CA1), Shangliao (BL31), Ciliao (BL32), Zhongliao (BL33), Xialiao (BL34), Shuidao (ST28), Guilai (ST25), Shenshu (BL23), Pigen (EX-B4), Sanyinjiao (SP6) N N N N Two a week for 3 months Ma WJ 2023 35 Combination therapy AC+WM: Geshu (BL17), Taichong (LR3), Xuehai (SP10), Qihai (CV6), Sanyinjiao (SP6) 30 min N N N Once a day for 3 months Yu WT 2022 36 Combination therapy AA+CH: Shenque (CV8), Guanyuan (CV4), Qihai (CV6), Zigong (EX-CA1) 4h N N Stop treatment during menstruation Once a day for 3 months Lu S 2014 37 MOX Zhongji (CV3), Guanyuan (CV4), Qihai (CV6) 30 min N N N Three a week for 3 weeks Zhang XH 2017 38 Combination therapy MOX+CH: Guanyuan (CV4), Shenque (CV8), Zigong (EX-CA1), Sanyinjiao (SP6), Xuehai (SP10), Diji (SP8) N N N Treatment is started 2 days before menstruation until menstruation occurs Once a day for 3 months Niu XX 2012 39 MOX Guanyuan (CV4), Zhongji (CV3), Zigong (EX-CA1), Sanyinjiao (SP6) N N N Treatment is started 1–2 days before menstruation until menstruation occurs Once a day for 3 months Combination therapy MOX+CH: Guanyuan (CV4), Zhongji (CV3), Zigong (EX-CA1), Sanyinjiao (SP6) N N N Treatment is started 1–2 days before menstruation until menstruation occurs Once a day for 3 months An XY 2016 40 AA Shenque (CV8), Zhongji (CV3), Zigong (EX-CA1), Ciliao (BL32) 6h N N N Once a day for 3 months Chen YB 2021 41 Combination therapy MOX+WM: Guanyuan (CV4), Zigong (EX-CA1), Xuehai (SP10) 30 min N N N Every other day for 3 months Xu LP 2017 42 Combination therapy MOX+CH: Ashi points, Guanyuan (CV4), Qihai (CV6), Qugu (CV2), Sanyinjiao (SP6), Zusanli (ST36), Shenshu (BL23) 20–30 min N N Treatment is started 1 week before menstruation until menstruation occurs Once a day for 3 months Pan HL 2023 43 Combination therapy MOX+AA: Shenque (CV8), Qihai (CV6), Guilai (ST25), Shenshu (BL23), Shangliao (BL31), Ciliao (BL32), Zhongliao (BL33), Xialiao (BL34), Ashi points 20 min N N Treatment starts in the second half of the menstrual cycle for 10 consecutive sessions Once a day for 3 months Wei W 2015 44 Combination therapy AC+CH: Zhongji (CV3), Guanyuan (CV4), Daheng (SP15), Tianshu (ST25), Wailing (ST26), Zusanli (ST36), Sanyinjiao (SP6) 20 min N N N 3 months Ru HM 2015 45 Combination therapy AC+CH: Sanyinjiao (SP6), Qixue (KI13), Dahe (KI12), Zigong (EX-CA1), Diji (SP8), Taixi (KI3), Qihai (CV6), Guanyuan (CV4) N N N N 3 months Liu YL 2023 46 Combination therapy ACE+WM: Shenque (CV8), Guanyuan (CV4), Qihai (CV6), Zhongji (CV3), Zigong (EX-CA1) N N N N Once a day for 12 weeks Yu L 2021 47 Combination therapy ACE+CH:Shenshu (BL23) N N N N Once a month for 12 months Wu JX 2013 48 Combination therapy EA+CH enema: Zhongji (CV3), Guanyuan (CV4), Zigong (EX-CA1), Sanyinjiao (SP6), Diji (SP8), Xuehai (SP10), Taichong (LR3) 40 min N Y N Once a day for 3 months Zhao JQ 2023 49 Combination therapy AC+CH: Sanyinjiao (SP6), Qihai (CV6), Baihui (GV20) 50 min N Y N Six a week for 3 months Wan YT 2022 50 Combination therapy AA+CH: Shenque (CV8), Guilai (ST25), Zigong (EX-CA1), Guanyuan (CV4), Shenshu (BL23), Yaoyangguan (GV3) 2 h N N Treatment for 14 days after the end of menstruation Once a day for 3 months Fang LX 2018 51 Combination therapy ACE+CH: Diji (SP8), Sanyinjiao (SP6), Shenshu (BL23), Xuehai (SP10) N N N N Two a week for 5 months ACE Diji (SP8), Sanyinjiao (SP6), Shenshu (BL23), Xuehai (SP10) N N N N Two a week for 5 months Dong Q 2022 52 Combination therapy MOX+CH: Xuehai (SP10), Sanyinjiao (SP6), Zigong (EX-CA1), Tianshu (ST25), Guanyuan (CV4), Zhongji (CV3) 10 min N N Treatment is started 2 days before menstruation until menstruation occurs Once a day for 3 months MOX Xuehai (SP10), Sanyinjiao (SP6), Zigong (EX-CA1), Tianshu (ST25), Guanyuan (CV4), Zhongji (CV3) 10 min N N N Once a day for 3 months Zeng R 2010 53 Combination therapy AC+MOX: Guanyuan (CV4), Zhongji (CV3), Tianshu (ST25), Zusanli (ST36), Sanyinjiao (SP6), Taichong (LR3) 30 min N Y N Once a day for 2 months AC Guanyuan (CV4), Zhongji (CV3), Tianshu (ST25), Zusanli (ST36), Sanyinjiao (SP6), Taichong (LR3) 30 min N Y N Once a day for 2 months Wang YJ 2018 54 Combination therapy MOX+CH: Guanyuan (CV4), Qihai (CV6), Zhongji (CV3), Sanyinjiao (SP6), Hegu (LI4) 30 min N N Treatment is started 3 days before menstruation until menstruation occurs Once a day for 3 months Zuo DD 2020 55 Combination therapy ACE+WM: Guanyuan (CV4), Tianshu (ST25), Zhongji (CV3), Zigong (EX-CA1), Diji (SP8), Qihai (CV6), Ciliao (BL32), Taichong (LR3), Xuehai (SP10), Zusanli (ST36), Sanyinjiao (SP6) N N N N Once a month for 3 months Cong HF 2018 56 ACE Sanyinjiao (SP6), Xuehai (SP10), Diji (SP8), Zigong (EX-CA1), Guanyuan (CV4) N N N N Once a week for 12 weeks AC Sanyinjiao (SP6), Xuehai (SP10), Diji (SP8), Zigong (EX-CA1), Guanyuan (CV4) 30 min N Y N Three a week for 12 weeks Men JN 2023 57 Combination therapy ACE+CH: Shenshu (BL23), Ciliao (BL32), Qihai (CV6), Guanyuan (CV4), Tianshu (ST25), Zigong (EX-CA1), Zusanli (ST36), Sanyinjiao (SP6) N N N N Once a month for 3 months Zhang MY 2017 58 Combination therapy ACE+CH: Shenshu (BL23), Sanyinjiao (SP6), Ciliao (BL32), Zigong (EX-CA1), Xuehai (SP10), Guanyuan (CV4) N N N N N Xi LL 2021 59 Combination therapy AC+WM: Zigong (EX-CA1), Xuehai (SP10), Sanyinjiao (SP6), Hegu (LI4), Taichong (LR3) 30 min N Y N Every other day for 3 months Zhang CM 2023 60 Combination therapy AC+CH: Zhongwan (CV12), Qihai (CV6), Guanyuan (CV4), Zhongji (CV3) 30 min N Y Stop treatment during menstruation Two a week for 12 weeks AC Zhongwan (CV12), Qihai (CV6), Guanyuan (CV4), Zhongji (CV3) 30 min N Y Stop treatment during menstruation Two a week for 12 weeks Chen M 2010 61 Combination therapy AC+AA: Zhongji (CV3), Guanyuan (CV4), Zigong (EX-CA1), Sanyinjiao (SP6) N N N N Once a day for 3 months Feng Y 2014 62 Combination therapy AC+CH: Qihai (CV6), Guanyuan (CV4), Sanyinjiao (SP6), Qixue (KI13), Dahe (KI12), Zigong (EX-CA1), Diji (SP8), Taixi (KI3) 30 min N Y Treatment starts 3–5 days before menstruation for 7 consecutive days Once a day for 3 months Li X 2020 63 Combination therapy ACE+CH enema: Shenshu (BL23) N N N N Two a month for 3 months Hu YG 2019 64 Combination therapy MOX+CH: Shenshu (BL23), Zhongji (CV3), Ciliao (BL32), Zigong (EX-CA1), Qihai (CV6), Guanyuan (CV4), Sanyinjiao (SP6) 15–20 min N N N Once a day for 12 weeks Liu ZX 2016 65 Combination therapy MOX+CH: Zigong (EX-CA1), Zhongji (CV3), Ciliao (BL32), Guanyuan (CV4), Qihai (CV6), Shenshu (BL23), Zusanli (ST36), Fenglong (ST40), Sanyinjiao (SP6) 15–20 min N N Treatment starts 1 days before menstruation for 7 consecutive days Once a day for 3 months Du X 2010 66 Combination therapy AT+CH: Neishengzhiqi (TF 2 ), Gan (CO 12 ), Yidan (CO 11 ), Shen (CO 10 ), Fu (AH 8 ), Shengshangxian (TG 2p ), Erbeigou (P S ), Ermigen (R 2 ), Pizhixia (AT 4 ), Neifenmi (CO 18 ) 2–3 min N N N 2–3 times a week for 6 months Notes : Y, reported; N, No reported. Abbreviations :AC, acupuncture; EA, electro-acupuncture; MOX, moxibustion; AT, auricular therapy; ACE, acupoint catgut embedding; AA, acupoint application; CH, Chinese herb medicine; WM, western medicine; UC, usual care; sAC, sham acupuncture. Figure 1 Flow diagram of preferred reporting items identified, included, and excluded for systematic reviews and meta-analyses (PRISMA). Baseline Characteristics of the Included Studies Abbreviations : CMA, Chinese Medical Association; PD, Pathologic Diagnosis; GCTNPCM, Guideline for Clinical Trials of New Patent Chinese Medicines; COG, Chinese Obstetrics & Gynecology; OG, Obstetrics and Gynecology; GTCM, Gynecologic Terms in Chinese Medicine; CAIM, Chinese Association of Integrative Medicine; AC, acupuncture; EA, electro-acupuncture; MOX, moxibustion; AT, auricular therapy; ACE, acupoint catgut embedding; AA, acupoint application; CH, Chinese herb medicine; WM, western medicine; UC, usual care; sAC, sham acupuncture. ① VAS scores; ② CA125; ③ response rate. Descriptions of the Included Acupuncture and Related Therapies That are Included Notes : Y, reported; N, No reported. Abbreviations :AC, acupuncture; EA, electro-acupuncture; MOX, moxibustion; AT, auricular therapy; ACE, acupoint catgut embedding; AA, acupoint application; CH, Chinese herb medicine; WM, western medicine; UC, usual care; sAC, sham acupuncture. Flow diagram of preferred reporting items identified, included, and excluded for systematic reviews and meta-analyses (PRISMA). The risk of bias for each trial is shown in Figure 2 . In 42 trials, 32 studies (76.19%) had a low risk, 9 studies (21.43%) had an unclear risk, and 1 study (2.38%) had a high risk for the random sequence generation (Kappa=0.675). Four studies (9.52%) had a low risk, 38 studies (90.48%) had an unclear risk of allocation concealment (Kappa=1). One study (2.38%) had a low risk, 41 studies (97.62%) had a high risk of blinding of participants and personnel (Kappa=0.656). Three studies (7.14%) had a low risk, 39 studies (92.86%) had an unclear risk of blinding of outcome assessment (Kappa=1). Thirty studies (71.43%) had a low risk, 12 studies (28.57%) had an unclear risk of blinding of incomplete outcome data (Kappa=0.667). Forty-two studies (100%) had a low risk for the selective reporting (Kappa=1) and other bias (Kappa=1). Figure 2 Quality assessment of included studies. Quality assessment of included studies. Pairwise meta-analyses show that combination therapy was more efficacious than WM and CH for pain VAS, CA125 and response rate results ( Table 3 ). Table 3 Pairwise Meta-Analyses Comparison Pairwise RR/MD (95% CI) Number of Patients Number of Studies Heterogeneity Test I 2 (%) p value Pain VAS scores Combination therapy vs WM −1.801[−2.349 −1.254] 641 8 82.90 0.000 * Combination therapy vs CH −1.119[−1.327 −0.911] 341 4 0.00 0.000 * Serum CA125 level Combination therapy vs WM −6.720[−9.363 −4.077] 639 8 61.30 0.000 * Combination therapy vs CH −4.566[−6.036 −3.095] 406 5 0.00 0.000 * Response rate Combination therapy vs WM 1.112[1.023 1.208] 1444 15 0.00 0.012 * Combination therapy vs CH 1.178[1.028 1.349] 666 7 0.00 0.019 * Combination therapy vs AC 1.222[0.776 1.926] 160 2 0.00 0.387 Notes : *Significant difference. Abbreviations :WM, western medicine; CH, Chinese herb medicine; AC, acupuncture. Pairwise Meta-Analyses Notes : *Significant difference. Abbreviations :WM, western medicine; CH, Chinese herb medicine; AC, acupuncture. Three network plots were constructed using Stata 15.0. The thicker the line, the more studies there are on the two intervention measures, and circle size is positively correlated with the sample size of patients for the corresponding intervention ( Figure 3 ). Figure 3 The network structure for treatment comparisons. ( A ) pain VAS scores; ( B ) serum CA125 level; ( C ) response rate. AC, acupuncture; EA, electroacupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AT, auricular therapy; AA, acupoint application; ACE, acupoint catgut embedding; WM, hormone drugs; UC, usual care; sAC, sham acupuncture. The network structure for treatment comparisons. ( A ) pain VAS scores; ( B ) serum CA125 level; ( C ) response rate. AC, acupuncture; EA, electroacupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AT, auricular therapy; AA, acupoint application; ACE, acupoint catgut embedding; WM, hormone drugs; UC, usual care; sAC, sham acupuncture. 17 studies reported pain VAS scores, involving eight interventions and 1,305 patients. The findings of the NMA indicated that AC was more effective than WM (SMD: −2.33; 95% CI: −4.37, −0.29). Furthermore, combination therapy demonstrated superior efficacy compared to CH (SMD: 1.07; 95% CI: 0.23, 1.92), UC (SMD: 2.57; 95% CI: 0.12, 5.02), and WM (SMD: 1.79; 95% CI: 1.21, 2.41) ( Table 4 ). The results of the ranking exercise indicated that the four most effective interventions in reducing the VAS scores were ACE (76.8%), AA (70.1%), AC (66.6%), and combination therapy (66.6%), while the least effective was WM (10.2%; Figure 4A ). Table 4 Network Meta-Analysis Results Pain VAS Scores AA 0.93 (−1.69, 3.56) AC 1.24 (−1.88, 4.33) 0.30 (−1.36, 1.94) ACE −0.67 (−2.63, 1.27) −1.60 (−3.35, 0.16) −1.91 (−4.32, 0.53) CH −2.18 (−5.17, 0.84) −3.11 (−6.24, 0.05) −3.42 (−6.95, 0.19) −1.51 (−4.10, 1.11) UC −1.40 (−3.05, 0.24) −2.33 (−4.37, −0.29)* −2.63 (−5.26, 0.01) −0.73 (−1.77, 0.31) 0.78 (−1.75, 3.28) WM 0.40 (−1.35, 2.15) −0.54 (−2.48, 1.43) −0.84 (−3.38, 1.75) 1.07 (0.23, 1.92)* 2.57 (0.12, 5.02)* 1.79 (1.21, 2.41)* Combination therapy 0.86 (−2.23, 3.98) −0.07 (−1.68, 1.55) −0.37 (−2.67, 1.93) 1.54 (−0.86, 3.93) 3.04 (−0.52, 6.56) 2.26 (−0.35, 4.88) 0.47 (−2.08, 3.00) sAC Serum CA125 Level AA −10.40 (−19.29, −0.88)* AC −9.57 (−17.79, −1.96)* 0.89 (−6.77, 7.04) CH −11.33 (−20.28, −2.97)* −0.89 (−9.35, 6.11) −1.80 (−6.42, 2.96) MOX −11.86 (−18.81, −4.86)* −1.44 (−7.71, 4.07) −2.32 (−5.72, 1.89) −0.57 (−5.21, 4.95) WM −5.14 (−12.93, 1.99) 5.27 (−1.94, 11.07) 4.41 (1.59, 7.24)* 6.20 (1.60, 10.75)* 6.75 (3.72, 8.94)* Combination therapy −8.66 (−25.95, 8.57) 1.66 (−12.90, 15.80) 0.92 (−14.98, 16.78) 2.66 (−13.56, 19.01) 3.13 (−12.56, 18.68) −3.50 (−19.30, 12.26) sAC Response Rate AA 3.69 (0.66, 27.16) AC 2.13 (0.32, 14.73) 0.56 (0.14, 2.22) ACE 0.37 (0.03, 3.14) 0.10 (0.01, 0.56) 0.18 (0.02, 1.19) AT 3.10 (0.68, 15.62) 0.85 (0.27, 2.30) 1.48 (0.42, 5.24) 8.01 (2.08, 45.37)* CH 0.89 (0.06, 18.16) 0.25 (0.02, 2.68) 0.42 (0.03, 5.41) 2.40 (0.52, 14.45) 0.29 (0.03, 3.10) EA 1.81 (0.37, 10.57) 0.49 (0.14, 1.67) 0.88 (0.21, 3.75) 4.99 (0.92, 34.10) 0.60 (0.23, 1.49) 2.09 (0.18, 25.26) MOX 3.98 (0.99, 17.89) 1.09 (0.39, 2.67) 1.94 (0.55, 6.39) 10.50 (2.40, 64.97)* 1.30 (0.72, 2.29) 4.46 (0.46, 49.01) 2.20 (0.92, 5.18) WM 0.80 (0.19, 3.75) 0.22 (0.08, 0.53)* 0.39 (0.12, 1.23) 2.11 (0.50, 12.46) 0.26 (0.16, 0.41)* 0.91 (0.09, 9.31) 0.44 (0.19, 1.04) 0.20 (0.14, 0.29)* Combination therapy Notes : *Bold values indicate significant difference. Abbreviations : AC, acupuncture; EA, electroacupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AT, auricular therapy; AA, acupoint application; ACE, acupoint catgut embedding; WM, hormone drugs; UC, usual care; sAC, sham acupuncture. Figure 4 The surface under the cumulative ranking curves (Graphs by Treatment). ( A ) pain VAS scores; ( B ) serum CA125 level; ( C ) response rate. AC, acupuncture; EA, electroacupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AT, auricular therapy; AA, acupoint application; ACE, acupoint catgut embedding; WM, hormone drugs; UC, usual care; sAC, sham acupuncture. Network Meta-Analysis Results Notes : *Bold values indicate significant difference. Abbreviations : AC, acupuncture; EA, electroacupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AT, auricular therapy; AA, acupoint application; ACE, acupoint catgut embedding; WM, hormone drugs; UC, usual care; sAC, sham acupuncture. The surface under the cumulative ranking curves (Graphs by Treatment). ( A ) pain VAS scores; ( B ) serum CA125 level; ( C ) response rate. AC, acupuncture; EA, electroacupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AT, auricular therapy; AA, acupoint application; ACE, acupoint catgut embedding; WM, hormone drugs; UC, usual care; sAC, sham acupuncture. A total of 18 studies were identified that reported on CA125, involving seven distinct interventions and 1,457 patients. The analysis results of the NMA demonstrated that AA was more effective than AC SMD: (−10.4095% CI: −19.29, −0.88), CH (SMD: −9.57 95% CI: −17.79, −1.96), MOX (SMD: −11.33 95% CI: −20.28, −2.97), and WM (SMD: −11.86 95% CI: −18.81, −4.86). The combination therapy demonstrated superior efficacy compared to CH (SMD: 4.41; 95% CI: 1.59, 7.24), WM (SMD: 6.20; 95% CI: 1.60, 10.75) and MOX (SMD: 6.75; 95% CI: 3.72, 8.94) ( Table 4 ). The ranking results of the ranking indicated that the top four interventions for increasing the response rate were AA (86.3%), combination therapy (79.8%), sAC (48.9%), and AC (46.0%), while the worst was MOX (17.2%) ( Figure 4B ). A total of 33 studies were identified that reported response rates involving nine distinct interventions and 2,969 patients. The findings of the NMA indicated that the combination therapy was more efficacious than CH (SMD: 0.26; 95% CI: 0.16, 0.41) and WM (SMD: 0.20; 95% CI: 0.14, 0.29). The results demonstrated that AT was more effective than WM (SMD:8.01; 95% CI: 2.08, 45.37) ( Table 4 ). The results of the ranking indicated that the top four interventions to increase the response rate were AT (93.2%), combination therapy (77.2%), AA (68.3%), and EA (67.5%), while the least effective was WM (11.2%) ( Figure 4C ). The inconsistency test results indicate that the serum CA125 level included four closed loops, with the IF with 95% confidence interval (CI) of these closed loops containing 0, suggesting the absence of any significant inconsistencies ( Figure 5A ). The results of the inconsistency test indicate that the response rate included four closed-loop studies, for which the 95% CI contained 0, suggesting the absence of any significant inconsistencies ( Figure 5B ). As illustrated in the funnel plot, all included studies are symmetrically distributed on both sides of the vertical line X = 0, indicating a very low probability of a small sample effect ( Figure 6 ). Figure 5 Inconsistency test. ( A ) serum CA125 level; ( B ) response rate. AC, acupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; ACE, acupoint catgut embedding; WM, hormone drugs. Figure 6 Funnel diagram. AC, acupuncture; EA, electroacupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AT, auricular therapy; AA, acupoint application; ACE, acupoint catgut embedding; WM, hormone drugs. Inconsistency test. ( A ) serum CA125 level; ( B ) response rate. AC, acupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; ACE, acupoint catgut embedding; WM, hormone drugs. Funnel diagram. AC, acupuncture; EA, electroacupuncture; MOX, moxibustion; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AT, auricular therapy; AA, acupoint application; ACE, acupoint catgut embedding; WM, hormone drugs. Of the 42 included trials, 7 reported adverse events ( Table 5 ). Three WM-related trials reported adverse consequences such as irregular vaginal bleeding, headache, nausea and more. Five studies with acupuncture and related therapies reported subcutaneous hematoma, skin occurs, dizziness and more. One study with CH reported subcutaneous flashes, vaginal bleeding, and vaginal dryness. In general, the lower incidence of adverse events in the treatment of EMs with acupuncture-related therapies compared with western medicine suggests the safety of acupuncture-related therapies. Table 5 Adverse Events References Adverse Events Li P S 2023 25 AC: 3 cases of subcutaneous hematoma (3/51). sAC: 3 cases of subcutaneous hematoma (1/53). Chen LN 2010 31 WM: 2 cases of abdominal distension and nausea (2/26). Yu WT 2022 36 AA: itchy skin occurs in a few cases. Yu L 2021 47 WM:3 cases of irregular vaginal bleeding (3/30), 2 cases of breast tenderness (2/30), 2 cases of nausea (2/30), 1 case of headache (1/30). Zuo DD 2020 55 Combination therapy: 1 case of dizzy (1/43), 1 case of stomach discomfort (1/43). Men JN 2023 57 Combination therapy:1 case of vaginal dryness (1/52), 2 cases of vaginal bleeding (2/52). CH:1 case of hot flashes (1/47), 1 case of vaginal bleeding (1/47), 1 case of vaginal dryness (1/47). Zhang MY 2017 58 Combination therapy:1 case of nausea (1/60). WM: 6 cases of nausea (6/60), 2 cases of vertigo (2/60), 1 case of vomiting (1/60), 3 cases of sweating (3/60), 1 case of flustered (1/60). Abbreviations : AC, acupuncture; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AA, acupoint application; WM, hormone drugs; sAC, sham acupuncture. Adverse Events Abbreviations : AC, acupuncture; CH, Chinese herb medicine; combined therapies, the combination of acupuncture-related therapies and other therapies; AA, acupoint application; WM, hormone drugs; sAC, sham acupuncture.

A comprehensive network meta-analysis evaluated and compared the efficacy and safety of a range of acupuncture-therapies for endometriosis, encompassing electro-acupuncture, moxibustion, auricular therapy, and nearly all other related techniques. The effectiveness of pain VAS scores, serum CA125 level, response rate, and adverse events was evaluated through the analysis of 42 eligible RCTs, which included a total of 3,656 participants. Pairwise meta-analyses show that combination therapy was superior to both WM and CH in reducing pain scores, decreasing serum CA125 levels, and increasing response rate. The NMA analysis results indicate that: for pain VAS scores, all acupuncture-related was more efficacious than WM and the ranking results showed that the top one was ACE. For serum CA125 level, all acupuncture-related was more efficacious than WM and the ranking results showed that the top one was AA. For response rate, all acupuncture-related was more efficacious than WM and the ranking results showed that the top one was AT. Safety analyses indicate that the lower incidence of adverse events in the treatment of EMs with acupuncture-related therapies compared with western medicine. EMs occurrence involves many factors, including distinctive genetic, environmental, and immunological factor. 67 The theory of retrograde menstruation/ transplantation is further supported by the discovery that women with EMs have more menstrual blood flow and endometrial tissue debris than women without the disorder. 68 Chronic pain (dysmenorrhea, cyclic and acyclic lower abdominal pain) is a central problem for our patients. 69 The aim of treatment is also to relief of pain. The pain VAS measurement was originally used in the field of psychology as a means of assessing an individual’s overall sense of well-being. Woodforde and Merskey were first reported use of the VAS pain scale in patients presenting with a range of pain conditions. 70 At present, pain VAS is the most commonly used pain assessment scale in the field of EMs. 71 A study examined the VAS demonstrated excellent test–retest reliability and validity with an intraclass correlation coefficient (ICC) of 0.97 72 . This indicates that the VAS is a reliable tool for assessing pain intensity. For a long time, acupuncture-related therapies have been used to manage various types of gynaecological pain, and there is a lot of evidence to support its efficacy in gynaecological pain management. 14 , 73–76 More and more evidence indicates that acupuncture-related therapies can alleviate pain. 77 Numerous peripheral chemicals including neurotransmitters, neuropeptides, and cytokines are involved in acupuncture-related therapies inhibition of pain. Acupuncture can by modulating the inflammatory levels of Interleukin-1 beta, tumor necrosis factor-α, prostaglandin E2, and prostaglandin F2α to relieve pain. 55 , 78 , 79 In addition, acupuncture-related therapies can through spinal and supraspinal mechanisms to inhibition of pain. In the spinal cord, the inactivation of spinal microglia and astrocytes, respectively, mediates the immediate and long-term analgesic effects of acupuncture. 80 The brain regions related to the descending pain regulation system include the anterior cingulate cortex, the periaqueductal gray matter of the midbrain, and the rostral ventromedial area medulla. 81 Acupuncture-related therapies can achieve analgesic effects by inhibiting the activation of glial cells and regulating the functions of the corresponding brain regions. 82 The most frequently used biomarker for endometriosis is CA125. CA125 levels are used to assess the severity of endometriosis and the effectiveness of treatment and are a valuable tool for monitoring treatment progress and response. 83 However, some studies have shown that the biomarkers evaluated, including serum CA125 levels, cannot be evaluated in a meaningful manner, and the evidence is insufficient or of poor quality. 84 , 85 Dorien et al put forth the argument that CA-125 appears to exhibit diminished sensitivity, particularly in advanced stages of endometriosis, as opposed to all stages collectively, while its specificity can be poor due to its rise in other gynaecological diseases. 86 A summary of the literatures related to endometriosis reveal that current serum CA125 level still uses as an outcome indicator for evaluating the efficacy of interventions. However, the effects of various interventions on serum CA125 level are not the same. Whether serum CA125 level can be used as an improved outcome indicator for endometriosis remains to be further explored. It is suggested to use the special evaluation scale for endometriosis and more appropriate specific markers to evaluate the clinical efficacy of acupuncture-related therapies in the treatment of endometriosis in the future. With the continuous development of acupuncture, a variety of acupuncture-related therapies including electroacupuncture, auricular therapy, acupoint catgut embedding, acupoint application and so on have gradually formed. The current research suggests that acupuncture-related therapies have a positive clinical impact on a diverse range of diseases, with a broad spectrum of indications. The efficacy of acupuncture and related therapies in the treatment of various types of pain disorders has been confirmed. And compared with drug therapy, acupuncture and related therapies minimal and mild side effects, 87 which can effectively relieve nausea, dizziness, gastrointestinal discomfort and other symptoms caused by drugs. The relaxation effect and attention to individual patients during acupuncture treatment can bring psychological comfort and support, and help alleviate the psychological pressure caused by disease and drug treatment. 88 These studies show that acupuncture-related therapies have great potential for endometriosis. Compared to previously published researches, this study includes a comprehensive database, 14 a large number of included studies, and encompasses the latest RCT studies on endometriosis. 16 It also assesses almost all acupuncture-related therapies. 15 , 17 , 18 And that the NMA method employed in this study integrates both direct and indirect evidence, compensating for the scarcity of direct evidence through the inclusion of indirect evidence, thereby facilitating a comparative analysis of the efficacy of various acupuncture-related therapies for endometriosis. The results indicate that acupuncture-related treatments such as acupoint application, acupoint catgut embedding, and acupoint catgut embedding show potential therapeutic effects in alleviating the symptoms of endometriosis. It should be noted that our study is not without limitations. (1) The trials included in the study encompassed a broad spectrum of population characteristics and treatment cycles. Although the consistency of the findings across the studies mitigated this concern, it could still lead to imprecise estimates of the effects. (2) Almost all of participants were Chinese, which lacked diversity, and the rigor and scientificity of the content needed to be further verified. (3) The study exhibits a lack of consistency, with the diagnostic criteria for included research being diverse. The point selection of acupuncture-related therapies and the course of treatment were different which may introduce potentially heterogeneity and affect the level of evidence within the research. (4) Acupuncture-related therapies involve variety of methods, and it is difficult to form a closed loop between them. Therefore, this study classified them as combination therapy and could not specifically analyze which combination therapy is the best treatment mode.

Given our meta-analysis results, acupuncture-related therapies could be considered a potential treatment method and warrants further investigation. Among them, acupoint catgut embedding, auricular therapy, acupoint application and combination therapy may be the best solutions for the treatment of endometriosis. In subsequent investigations within this domain, it is imperative that clinical studies adhere rigorously to established guidelines and protocols.